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When I was growing up in an immigrant neighborhood in
Minneapolis, I would on occasion overhear someone ask,
‘‘How long have you known this or that person?’’ To my
surprise, instead of answering the number of years one
would hear: ‘‘We came over on the boat together.’’ I would
say to myself, why can’t these people answer with a
number—they know how to count. I finally came to realize
that the answer was a way of saying something affecting of
longtime friends. No number was needed. Fitzpatrick and I
worked together so closely, so long, and so productively, as
well as having such a major impact on each other’s lives, that
we qualify in saying ‘‘We came over on the boat together.’’
Fitzpatrick and I met at the Army Chemical Center in
Edgewood Arsenal, Maryland, in 1947. The Second World
War had been over for 2 years, but the military still needed
medical officers for many of its activities. Those of us who
were recent graduates were to serve for 2 years with the
rank of Captain. Nearly all of the officers assigned to the
Army Chemical Center were graduates from major medical
schools in the East—Harvard, Columbia, Cornell, Johns
Hopkins, and Yale. One or two of them were from schools in
the Midwest, but none that I can recall were from schools in
California. Fitzpatrick was from Harvard. I, along with about
17 other 1945 graduates, many from my class at Minnesota,
was assigned to the Veterans Mental Hospital in St Cloud,
Minnesota. The Army wanted to beef up the psychiatric
care for new veterans. For me it was a poor assignment. I
wanted a position in research. Writing to the Army
requesting something in research was not working, until
one of my letters was seen by Colonel John Wood when he
was meeting with the Surgeon General. John Wood was a
physician with excellent administrative talents who was
head of research at the Army Chemical Center. After reading
one of my letters, he told the Surgeon General that he could
use me. Two days later I was off to the Army Chemical
Center.
Fitzpatrick was in the Pathology Section, and I was
assigned to Biochemistry. In the first couple of days at the
Center I was making my own tour of the laboratories. One
person, Fitzpatrick, was particularly friendly and curious.
His wife, Bea, my late wife Marge, and I were all from
Minneapolis. Fitzpatrick grew up not far away in Madison,
Wisconsin. On that first visit Fitzpatrick stated that he was
going into dermatology when his tour of duty with the Army
was over. I told him that my long-term goal was to get into
pigmentation. My thesis for an MS degree at Minnesota was
on pigmentation. I had not settled on any clinical specialty,
but dermatology was always on my list. Being friends with
Walter Shelley in graduate school gave dermatology weight.
After discussions with Fitzpatrick for a week or two, we
considered to try to do a project together on pigmentation.
But first we had to do two things. We had to transfer
Fitzpatrick into the Biochemistry Section and we had to get
approval to work on a non-Army project in our free time.
The Biochemistry Section had just gotten a new Chief,
William H. Summerson. Summerson was a tenured profes-
sor of biochemistry at Cornell and an outstanding scientist
and teacher. He was a coauthor of a leading textbook on
biochemistry. Also, he was the first to make a useful
photometer with a photoelectric cell to measure absorption
of light by a solution—the Klett Summerson photometer.
In getting approval from Summerson to work on our project,
luck was with us. Years earlier, for his PhD thesis, Summer-
son showed that when animals are on a diet deficient in
copper they become anemic. Summerson knew that tyro-
sinase in plants contained copper. One of our goals was to
determine whether the pathway for pigment formation in
mammalian systems involved tyrosinase. Summerson was
still interested in copper metabolism. He approved the
project and he gave permission for Fitzpatrick to be
transferred into the Biochemistry Section.
Fitzpatrick and I spent a lot of time together to make an
outline for our research proposal. We would spend an hour
on the phone every morning. We decided to use the
HardingPassey mouse melanoma as the source of tissue
to study the mechanism of mammalian melanin formation.
Just as we were getting started, we were joined by Dr Evan
Calkins, a medical school classmate of Fitzpatrick’s. Evan
was a bright, colorful physician who added much to our
research. Within a few days things began to move. We were
on a fast-track, having a good time in finding out how
tyrosine is oxidized to melanin. Once Summerson called
Fitzpatrick and me into his office to tell us that we were
taking too much equipment from other laboratories. Both
Fitz and I were sad to hear of this charge because we had
so much respect for Summerson. About 2 weeks later,
Summerson came into the laboratory very upset. He said
that for his own experiments he needed a pH meter. None of
the three instruments that he tried in our laboratory worked.
He said that if we got him a good pH meter he would not ask
us where or how we got it. Within 10 minutes, we got him a
new instrument. He returned it to us later in the day and,
true to his word, he never asked where it came from.
Fitzpatrick and I learned how to circumvent the bureau-
cracy. We had an absolutely fabulous year at the Army
Chemical Center. We showed that mammalian pigment cells
contain an enzyme with two catalytic activities—tyrosinase,
which catalyzes the oxidation of tyrosine to dopa, and dopa
oxidase, which catalyzes the oxidation of dopa to dopa
quinone. Because the first reaction is with tyrosine, we kept
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the name tyrosinase and dropped dopa oxidase. We
studied the kinetics of the oxidation of tyrosine to melanin
and the role of dopa in the activation of tyrosinase.
Mammalian tyrosinase did contain copper. We also studied
the inhibition of tyrosinase. In 1950 Fitzpatrick and I wrote a
paper for Physiological Reviews on melanin pigmentation,
which brought the thoughts on that subject up to date.
During the year, all of the medical officers discussed and
supported their future plans with one another. Fitzpatrick
accepted a Dermatology residency at the Mayo Clinic, and I
was going to Western Reserve—now called Case Western
Reserve—on a fellowship from the American Cancer
Society to work with Harland Wood in biochemistry.
Fitzpatrick asked me to go with him to a Dermatology
meeting in Washington, DC. At a social gathering I met
Stephen Rothman from the University of Chicago and Arthur
Curtis from the University of Michigan. Curtis was the new
Chief of Dermatology at Michigan. He had been Professor of
Medicine who taught physical diagnosis, and he was an
outstanding clinician. He took a crash course in dermatol-
ogy at the Mayo Clinic before starting his Chairmanship.
Near the end of the evening, Curtis said that he wanted me
to visit with him in Ann Arbor. He offered me a position in his
department. In 1948, Fitzpatrick and I left the Army. My late
wife completed 2 years of medical school at Johns Hopkins
and transferred to Case Western Reserve so we could be
together.
Fitzpatrick was no ordinary resident at the Mayo Clinic. I
had a visit with him in his second year, and I saw him in
action. He was functioning as a senior resident, he was
working towards a PhD degree in pathology, and he was
researching tyrosinase in human skin.
Marge and I took up Curtis’s offer to see him in Ann
Arbor. He showed us around the department and the
medical school. He answered a lot of questions and he left
us with positive feelings. I would be an Assistant Professor
and Director of the research laboratories. At the same time I
would be resident in Dermatology. Fitzpatrick would also be
an Assistant Professor. Marge would be an intern and after
that a resident in Dermatology. Curtis gave me 1 year in
which to decide. The decision was not easy. Curtis was
quite generous, but things were going well in Cleveland.
Nevertheless, the chance to run an independent laboratory
and at the same time get clinical training in dermatology as
well as having a position for Fitzpatrick was too good to turn
down.
At the Mayo Clinic, Fitzpatrick was able to demonstrate
that tyrosinase existed in human skin. Years earlier (1917),
Bruno Bloch incubated fresh pieces of skin with dopa and
found that pigment granules showed up in the cytoplasm of
melanocytes. The enzyme responsible for this action was
called dopa oxidase. When tyrosine was used as the
substrate, nothing happened. With a slight but important
modification, Fitzpatrick exposed skin to ultraviolet light a
few days before taking a biopsy. Incubation of this irradiated
skin with tyrosine produced the same dark granules as did
dopa. Thus, human skin contains both tyrosinase and dopa
oxidase activities. Because these two activities existed in a
single enzyme in melanoma tissue, the situation is most
likely the same in human skin. Again, we dropped dopa
oxidase and kept the name tyrosinase.
At Case Western Reserve I wanted to solve a different
kind of pigment problem. It was known that when
homogentisic acid, a deviation of tyrosine, accumulates in
the body the darkening of ochronosis occurs. I wanted to
find out how homogentisic acid is metabolized. I made
phenylalanine with two labels: heavy carbon-C-13 in the
side chain and radioactive C-14 in the ring. I found that
normally phenylalanine is hydroxylated to tyrosine, which, in
turn, after a few steps, together with the movement of the
side chain, goes to homogentisic acid. The aromatic ring of
homogentisic acid is broken to give furmarylacetylacetic
acid, which then splits to furmaric and acetylacetic acids.
People with alkoptonuris lack the enzyme needed to
break the ring of homogentisic acid. The accumulation of
homogentisic acid produces the ochronosis seen in these
patients.
In 1949 I moved to Michigan and waited another year for
Fitzpatrick to come to Ann Arbor. In the meantime, I began
to work with a small drug company named Elder in Bryan,
Ohio, to test a new treatment for patients with vitiligo. The
patients would take 8-methoxypsoralen (8-MOP) by mouth
followed by exposure of the skin to sunlight. A resident, Dr
Clevelend Denton, helped in this study. Some patients were
getting excellent repigmentation. In another project, we
decided to pick up on the suggestion of Evan Calkins that
the pituitary gland plays a role in pigmentation. We began
by developing a test for this agent using small pieces of frog
skin in vitro. We named the factor melanocyte stimulating
hormone or MSH.
Even though things were going well, Fitzpatrick was
growing restless. He felt that the two of us could run a
department on our own. There were some openings to
consider. One was at the University of Washington in
Seattle. They were willing to give Fitzpatrick a tenured
position as Associate Professor and me a nontenured
position as Assistant Professor. The University of Oregon
Medical School in Portland, however, would give both of us
tenured positions with Fitzpatrick being a full professor and
me an associate professor. We accepted the Oregon offer.
Fitzpatrick was 32 years old. I was 31.
We began immediately to look for new people to add to
the Dermatology Section. Two were found. One was
Howard Mason, an organic chemist with a PhD degree
from MIT. The other was Kazuo Shizume, a medical school
graduate from the University of Tokyo interested in
endocrinology. Both were superb choices. The clinical and
research activities got moving fast. We began to attract
residents, and our relationship with dermatologists in the
community was going well. The clinical faculty at Oregon
was permitted to keep the money that they collected from
private patients. Fitzpatrick and I had a 50/50 partnership. In
addition to seeing private patients at the Medical School,
we alternated going to Astoria, Oregon, once a week to see
patients in a clinic there. Our partnership worked out well.
After all of our careful work in perfecting the assay for
MSH, the isolation of the hormone in pure form, and the
testing for toxicity in mice, we were ready to find out
whether or not MSH would darken human skin. There was
great excitement as we began to inject MSH into the first
volunteer. Every day on rounds our group was split as to
whether or not there was darkening. After 5 d the subject
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answered the question when he asked, ‘‘How much darker
are you going to let me get?’’ Howard Mason showed that in
the oxidation of tyrosine to dopa the oxygen comes from
the air and not from water.
Fitzpatrick and I were treating a lot of patients with
pigment problems—especially vitiligo and melanomas. For
vitiligo we were evaluating the use of 8-MOP both orally and
topically. Although medical oncology was coming into its
own as a specialty, we were treating patients with mela-
noma with TEPA and thio TEPA. It was striking to see that a
rapid regression was followed by an almost immediate
resistance.
In addition to his important role in perfecting the frog skin
assay for MSH, Dr Shizume had a major accomplishment in
advancing the flow of young medical school graduates from
Japan to train in the USA. He alone arranged for Dr Ataushi
Kukita and Yoshiyata Takahashi to come to Oregon. These
two were followed by many others. But it was Shizume who
was the first and got it going.
Fitzpatrick and I were extraordinarily independent peo-
ple. After three great years in Oregon, I accepted the
dermatology position at Yale. Even though we did not work
together again, we always supported one another. The un-
usual close feelings that are difficult to express continued.
We always knew how much of an effect we had on one
another. We always looked forward to our visits together.
I want to comment on a trait that Fitzpatrick and I shared:
the making up of new names or reviving of old ones. I am
always surprised by how many people are afraid to give
something a new name. Fitzpatrick and I had no such
difficulty. The following is an example. Fitzpatrick was
always annoyed by pathologists using the term ‘‘melano-
blast’’ for a mature pigment cell. The term was okay for an
immature pigment cell, but not for a mature one. When we
were in Oregon, I went to a pigment meeting in New York.
Fitzpatrick wanted to stay home. He gave me the assign-
ment to change the name. One possibility was ‘‘melano-
genocyte’’ – a melanin-forming cell. When I brought this
subject up at the meeting, everyone agreed to drop the term
‘‘melanoblast’’ for the adult cell, but no one wanted ‘‘mela-
nogenocyte’’. All agreed to use an old name, ‘‘melanocyte’’.
Another example is ‘‘chloasma’’—the darkening of the face
of women during pregnancy. But men can also have this
type of darkening. ‘‘Chloasma’’ is too restrictive. There was
a seldom-used word ‘‘malasma’’ that we could use in our
writing. Many of the names or abbreviations were original,
e.g., ‘‘melanosome’’, ‘‘8-MOP’’, ‘‘PUVA’’, ‘‘epidermal mela-
nin unit’’, and others.
No Fitzpatrick—Lerner story is complete without mention
of the late Dr Harvey Blank. Harvey was a dermatologist
who liked to think. And he was good at it. When he was at
Squibb, he asked Fitzpatrick and me to test the first of a
group of fluorosteroids on patients with atopic dermatitis. It
was obvious in 1 or 2 weeks that Harvey was on to
something potent. The management of Squibb, however,
said there was no future for the fluorinated compound: all
research must stop. Harvey told us to quit the testing. We
could not believe this turn of events. We pleaded with
Harvey to send us more of this new steroid. At the risk of
losing his job, he sent us more. Then, all of a sudden,
Squibb changed its mind again. Now it was dependent on
our data to get approval from Food and Drug to market a
fluorosteroid.
Years ago, when NIH funds were becoming available for
research and training grants, the three of us were frequently
on site visits to evaluate the proposals. It was routine to find
that the dermatology unit received no local support. When
we sensed that some money could be available from the
department of medicine or the medical school, we often
turned down the grant and requested that they come in with
a new proposal having some support from the institution.
Our recommendations were nearly always successful.
Fitzpatrick was a dynamic, highly productive medical
scholar. He had a keen competitive spirit, a great sense of
humor, and a love of chamber music. He was always on the
move, pushing to start this or to explain that. He had
unlimited curiosity and he was always optimistic. He
produced a major textbook on dermatology. He was the
founder of the important and successful Dermatology
Foundation. He, more than anyone else, established close
ties with dermatologists all over the world—particularly in
Japan, Europe, and India. All of these qualities made him
the leading dermatologist in the last half of the twentieth
century.
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Left to right: Aaron Lerner, Howard Mason, Thomas Fitzpatrick, 1977, courtesy of Dr. Aaron Lerner.
Left to right: Thomas Fitzpatrick, Howard Mason, Aaron Lerner, Kazuo Shizume, University of Oregon Medical School, 1955,
courtesy of Dr. Aaron Lerner.
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